| Dr Ramana V Kalli, MD | |
|
770 Pine St, Suite 310, Macon, GA 31201-2173 | |
| (478) 741-1118 | |
| (478) 750-9301 |
| Full Name | Dr Ramana V Kalli |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 52 Years |
| Location | 770 Pine St, Macon, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700951308 | NPI | - | NPPES |
| 00237817A | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 023174 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fairview Park Hospital | Dublin, GA | Hospital |
| Medical Center, Navicent Health (the) | Macon, GA | Hospital |
| Coliseum Medical Centers, Llc, Dba | Macon, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cardiopulmonary Associates, P.c. | 7517063969 | 4 |
| Health Services Of Central Georgia | 9638076730 | 205 |
News Archive
Patricia A. Furlong, Founding President and CEO of Parent Project Muscular Dystrophy, the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy, announced that PPMD will provide a grant to clinical sites participating in Acceleron Pharma's Phase 2 clinical study of ACE-031. These grants will help patients' families cover travel costs to and from the study site, and hotel rooms and meals during study visits.
The New York Times: "More than a million Americans enrolled in [limited benefit, or mini med,] plans think they have health insurance to protect them from financial catastrophe if they become seriously ill or hurt, [Senator John D.] Rockefeller said. 'In fact, they don't,' he said. 'It's worse than nothing because of the false expectations and the false hope,' Mr. Rockefeller said" at the Senate hearing.
The International Osteoporosis Foundation (IOF) and the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) have worked in partnership to develop a unique springtime meeting programme for healthcare professionals, researchers and young scientists. With over 5,500 participants, this has become the largest educational event and most vibrant clinical research forum for osteoporosis and osteoarthritis in Europe.
Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.
› Verified 9 days ago
| Entity Name | Health Services Of Central Georgia |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184679482 PECOS PAC ID: 9638076730 Enrollment ID: O20031217000270 |
News Archive
Patricia A. Furlong, Founding President and CEO of Parent Project Muscular Dystrophy, the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy, announced that PPMD will provide a grant to clinical sites participating in Acceleron Pharma's Phase 2 clinical study of ACE-031. These grants will help patients' families cover travel costs to and from the study site, and hotel rooms and meals during study visits.
The New York Times: "More than a million Americans enrolled in [limited benefit, or mini med,] plans think they have health insurance to protect them from financial catastrophe if they become seriously ill or hurt, [Senator John D.] Rockefeller said. 'In fact, they don't,' he said. 'It's worse than nothing because of the false expectations and the false hope,' Mr. Rockefeller said" at the Senate hearing.
The International Osteoporosis Foundation (IOF) and the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) have worked in partnership to develop a unique springtime meeting programme for healthcare professionals, researchers and young scientists. With over 5,500 participants, this has become the largest educational event and most vibrant clinical research forum for osteoporosis and osteoarthritis in Europe.
Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.
› Verified 9 days ago
| Entity Name | Cardiopulmonary Associates, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023183399 PECOS PAC ID: 7517063969 Enrollment ID: O20070502000240 |
News Archive
Patricia A. Furlong, Founding President and CEO of Parent Project Muscular Dystrophy, the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy, announced that PPMD will provide a grant to clinical sites participating in Acceleron Pharma's Phase 2 clinical study of ACE-031. These grants will help patients' families cover travel costs to and from the study site, and hotel rooms and meals during study visits.
The New York Times: "More than a million Americans enrolled in [limited benefit, or mini med,] plans think they have health insurance to protect them from financial catastrophe if they become seriously ill or hurt, [Senator John D.] Rockefeller said. 'In fact, they don't,' he said. 'It's worse than nothing because of the false expectations and the false hope,' Mr. Rockefeller said" at the Senate hearing.
The International Osteoporosis Foundation (IOF) and the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) have worked in partnership to develop a unique springtime meeting programme for healthcare professionals, researchers and young scientists. With over 5,500 participants, this has become the largest educational event and most vibrant clinical research forum for osteoporosis and osteoarthritis in Europe.
Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ramana V Kalli, MD 770 Pine St, Suite 310, Macon, GA 31201-2173 Ph: (478) 741-1118 | Dr Ramana V Kalli, MD 770 Pine St, Suite 310, Macon, GA 31201-2173 Ph: (478) 741-1118 |
News Archive
Patricia A. Furlong, Founding President and CEO of Parent Project Muscular Dystrophy, the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy, announced that PPMD will provide a grant to clinical sites participating in Acceleron Pharma's Phase 2 clinical study of ACE-031. These grants will help patients' families cover travel costs to and from the study site, and hotel rooms and meals during study visits.
The New York Times: "More than a million Americans enrolled in [limited benefit, or mini med,] plans think they have health insurance to protect them from financial catastrophe if they become seriously ill or hurt, [Senator John D.] Rockefeller said. 'In fact, they don't,' he said. 'It's worse than nothing because of the false expectations and the false hope,' Mr. Rockefeller said" at the Senate hearing.
The International Osteoporosis Foundation (IOF) and the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) have worked in partnership to develop a unique springtime meeting programme for healthcare professionals, researchers and young scientists. With over 5,500 participants, this has become the largest educational event and most vibrant clinical research forum for osteoporosis and osteoarthritis in Europe.
Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.
› Verified 9 days ago
Mrs. Mary E Mckinley, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 360 Hospital Dr, Suite 110, Macon, GA 31217 Phone: 478-841-2707 Fax: 478-841-2708 | |
Dr. Swathi Singanamala, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 640 Martin Luther King Jr Blvd, Suite 200, Macon, GA 31201 Phone: 478-745-5455 Fax: 478-803-5232 | |
Dr. Sebastian Alan Montgomery, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 380 Hospital Dr Ste 430, Macon, GA 31217 Phone: 478-751-0480 | |
Sagar Jayant Panse, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 890 2nd St, Suite 201, Macon, GA 31201 Phone: 478-745-4322 Fax: 478-750-8789 | |
Dr. Rana K Munna, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 107 Preston Ct, Macon, GA 31210 Phone: 478-238-0771 Fax: 478-238-6688 | |
Oliver Wendell Horne Iv, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1062 Forsyth St Ste 1b, Macon, GA 31201 Phone: 478-741-1208 | |
Thomas P Meyer, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 360 Hospital Dr Bldg D, Suite 200, Macon, GA 31217 Phone: 478-745-5476 Fax: 478-745-3768 |